[1]

Yang L, Renauer PA, Tang K, Saskin J, Zhou L, et al. 2026. OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Nature 652:740−751

doi: 10.1038/s41586-026-10149-8
[2]

Suchiita A, Sonkar SC. 2025. Revolutionizing immunotherapy: the next frontier in CAR T-cell engineering. Critical Reviews in Oncology/Hematology 211:104751

doi: 10.1016/j.critrevonc.2025.104751
[3]

Balkhi S, Zuccolotto G, Di Spirito A, Rosato A, Mortara L. 2025. CAR-NK cell therapy: promise and challenges in solid tumors. Frontiers in Immunology 16:1574742

doi: 10.3389/fimmu.2025.1574742
[4]

Sheridan C. 2023. Industry appetite for natural killer cells intensifies. Nature Biotechnology 41:159−161

doi: 10.1038/s41587-023-01671-5
[5]

Yu Y, Ho M. 2025. CAR NK cell therapy for solid tumors: potential and challenges. Antibody Therapeutics 8:275−289

doi: 10.1093/abt/tbaf019
[6]

Yi M, Li T, Niu M, Zhang H, Wu Y, et al. 2024. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduction and Targeted Therapy 9:176

doi: 10.1038/s41392-024-01868-3
[7]

Ozga AJ, Chow MT, Luster AD. 2021. Chemokines and the immune response to cancer. Immunity 54:859−874

doi: 10.1016/j.immuni.2021.01.012
[8]

Ma S, Yu J, Caligiuri MA. 2025. Natural killer cell–based immunotherapy for cancer. The Journal of Immunology 214:1444−1456

doi: 10.1093/jimmun/vkaf036
[9]

Kim YM, Tsai MK, Sun C, Laveroni O, Akana RV, et al. 2026. Engineering NK and T cells with metabolite-sensing receptors to target solid tumors. Nature Immunology 27:1039−1052

doi: 10.1038/s41590-026-02473-y
[10]

Luo J, Guo M, Huang M, Liu Y, Qian Y, et al. 2025. Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation. Signal Transduction and Targeted Therapy 10:78

doi: 10.1038/s41392-025-02158-2
[11]

Cichocki F, van der Stegen SJC, Miller JS. 2023. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies. Blood 141:846−855

doi: 10.1182/blood.2022016205
[12]

Laskowski TJ, Biederstädt A, Rezvani K. 2022. Natural killer cells in antitumour adoptive cell immunotherapy. Nature Reviews Cancer 22:557−575

doi: 10.1038/s41568-022-00491-0
[13]

Narváez-Pérez LF, Paz-Bermúdez F, Avalos-Fuentes JA, Campos-Romo A, Florán-Garduño B, et al. 2024. CRISPR/sgRNA-directed synergistic activation mediator (SAM) as a therapeutic tool for Parkinson's disease. Gene Therapy 31:31−44

doi: 10.1038/s41434-023-00414-0
[14]

Finney Rutten LJ, Ridgeway JL, Griffin JM. 2024. Advancing translation of clinical research into practice and population health impact through implementation science. Mayo Clinic Proceedings 99:665−676

doi: 10.1016/j.mayocp.2023.02.005